Simulations Plus

Quickening the pace of drug discovery with AI

GastroPlus® Newsletter July 2023

Expanding our Immunology and Oncology Drug Development Capabilities

“The integration of our industry-leading ADMET Predictor and GastroPlus® mechanistic PBPK simulations into the initial generative chemical design process is what sets us apart from other machine learning drug design companies,” says AIDD Principal Scientist and former City of Hope Professor Jeremy Jones. “Our platform offers everything a medicinal chemist would want, at incredible speed.”

Simulations Plus is excited to announce that we are the recipients of a Comparably Award for “Best Company for Women” in 2022.

Merry Christmas and Happy Holidays!

With more than 20 years of industry experience, Chief Science Officer of DILIsym Services, Scott Q. Siler describes it this way, “think of modeling like photography.”